Technical Analysis for EXEL - Exelixis, Inc.

Grade Last Price % Change Price Change
B 23.17 0.83% 0.19
EXEL closed up 0.83 percent on Monday, March 18, 2024, on approximately normal volume. The price action carved out a bearish shooting star candlestick pattern. That may indicate a downside reversal. Look for price to trade beneath the low of the shooting star for confirmation. Due to the stock's strong uptrend, it may remain overbought for a while. So, if you're looking for a reason to sell, don't put too much weight on it being overbought.
3 Watchers
Watchlist Portfolio

Trend Table & Recent EOD Trading Signals

ADX Long Term Intermediate Term Short Term
Strong Up Up Up

Date Alert Name Type % Chg
Shooting Star Candlestick Bearish 0.00%
Doji - Bearish? Reversal 0.00%
Gapped Up Strength 0.00%
Overbought Stochastic Strength 0.00%
Pocket Pivot Bullish Swing Setup 0.83%
Inside Day Range Contraction 0.83%
Overbought Stochastic Strength 0.83%
Overbought Stochastic Strength 2.48%
Overbought Stochastic Strength 0.43%
Up 3 Days in a Row Strength 0.43%

   Recent Intraday Alerts

Alert Time
Rose Above Previous Day's High about 14 hours ago
Up 1% about 14 hours ago
60 Minute Opening Range Breakout 3 days ago
Possible NR7 3 days ago
Possible Inside Day 3 days ago

Free Daily (Stock) Chart Reading

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.

Profile

Exelixis, Inc. Description

Exelixis, Inc., a biotechnology company, engages in developing small molecule therapies for the treatment of cancer in the United States. It focuses on developing and commercializing COMETRIQ (cabozantinib), an inhibitor of multiple receptor tyrosine kinases for the treatment of progressive, metastatic medullary thyroid cancer. COMETRIQ is also involved in various other cancer indications, including two ongoing Phase III pivotal trials in metastatic castration-resistant prostate cancer; and two additional Phase III pivotal trials in metastatic hepatocellular cancer and metastatic renal cell cancer. In addition, the company has a portfolio of other novel compounds that address serious unmet medical needs. Exelixis, Inc. has collaborations with Bristol-Myers Squibb Company, Sanofi, Genentech, Inc., GlaxoSmithKline, Merck, and Daiichi Sankyo Company Limited for the development and commercialization of various compounds. The company was formerly known as Exelixis Pharmaceuticals, Inc. and changed its name to Exelixis, Inc. in February 2000. Exelixis, Inc. was founded in 1994 and is headquartered in South San Francisco, California.


Classification

Sector: Healthcare
Industry: Biotechnology
Keywords: Biotechnology Cancer Treatment Of Cancer Prostate Cancer Protein Kinase Inhibitor Tyrosine Kinase Thyroid Progressive Small Molecule Therapies Pivotal Resistant Prostate Cancer Tyrosine Kinase Inhibitors Cyclopropanes Metastatic Castration Resistant Prostate Cancer Receptor Tyrosine Kinase Thyroid Cancer Daiichi Sankyo Tyrosine Kinases

Is EXEL a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength

Indicators

Indicator Value
52 Week High 24.34
52 Week Low 17.9
Average Volume 2,366,041
200-Day Moving Average 21.29
50-Day Moving Average 21.90
20-Day Moving Average 22.09
10-Day Moving Average 22.59
Average True Range 0.49
RSI (14) 64.91
ADX 27.62
+DI 29.61
-DI 14.92
Chandelier Exit (Long, 3 ATRs) 21.96
Chandelier Exit (Short, 3 ATRs) 21.84
Upper Bollinger Bands 23.54
Lower Bollinger Band 20.64
Percent B (%b) 0.87
BandWidth 13.12
MACD Line 0.38
MACD Signal Line 0.25
MACD Histogram 0.1325
Fundamentals Value
Market Cap 7.03 Billion
Num Shares 303 Million
EPS 0.65
Price-to-Earnings (P/E) Ratio 35.65
Price-to-Sales 3.35
Price-to-Book 2.71
PEG Ratio 1.52
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 23.71
Resistance 3 (R3) 23.73 23.58 23.62
Resistance 2 (R2) 23.58 23.44 23.57 23.59
Resistance 1 (R1) 23.37 23.35 23.48 23.35 23.56
Pivot Point 23.22 23.22 23.27 23.21 23.22
Support 1 (S1) 23.01 23.08 23.12 22.99 22.78
Support 2 (S2) 22.86 22.99 22.85 22.75
Support 3 (S3) 22.65 22.86 22.72
Support 4 (S4) 22.63